"Epithelial surfaces in the human body are not only a physical barrier - they are crucial in maintaining healthy relationships with our microbiome and orchestrating defences against pathogens."
Professor Gudmundur Gudmundsson
CSO & Founder
OUR THERAPEUTIC FOCUS
Loss of epithelial immunity is a key driver of disease pathogenesis
Epithelial tissues cover our internal and external surfaces, forming not just a physical barrier between our organs and the external environment, but playing an active and dynamic
immunologic role in our body's defenses.
Many diseases are now recognised as being driven by loss of immunological integrity of epithelia, triggering a range of pathologies, including infection, inflammation and autoimmunity.
This common disease pathology is the focus of Akthelia's powerful host-directed therapeutic approach, with potential application to diseases of the skin, airway, gut, oral mucosa and urogenitary system, as well as systemic infections and inflammatory disorders.
UNIQUE HOST-DIRECTED APPROACH
Therapeutic science leveraging the power of millions of years of cooperative evolution
Decades of research by our founding scientists, have led us to a powerful therapeutic approach that mimics and enhances the effects of natural metabolites released by microbiota to maintain the integrity and health of their epithelial niche.
Our candidate therapeutic molecules are designed to amplify these effects, enhancing the immune status of the epithelial surface, restoring its barrier function and rejuvenating its relationships with the surrounding biology.
OUR LATEST NEWS
PARTNERS
Our
Collaborators
Great science needs great partners and we're proud to be collaborating with so many best-in-class organisations and research institutions to drive our research and development efforts forwards.
UNIVERSITY OF ICELAND
KAROLINSKA INSTITUTE
THERAINDX LIFESCIENCES
EVOTEC
ENAMINE BIENTA
UNIVERSITY OF NORTH TEXAS
RECIPHARM
MEWBURN ELLIS